Oncotarget

Research Papers: Immunology:

Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice

Fei-Ting Hsu, Tzu-Chun Chen, Hui-Yen Chuang, Ya-Fang Chang and Jeng-Jong Hwang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:44134-44150. https://doi.org/10.18632/oncotarget.6628

Metrics: PDF 1115 views  |   HTML 1526 views  |   ?  


Abstract

Fei-Ting Hsu1,2,3,*, Tzu-Chun Chen1,4,*, Hui-Yen Chuang1, Ya-Fang Chang1 and Jeng-Jong Hwang1,5

1 Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan

2 Department of Medical Imaging, Taipei Medical University Hospital, Taipei, Taiwan

3 Translational Imaging Research Center, College of Medicine, Taipei Medical University, Taipei, Taiwan

4 Department of Radiation Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan

5 Biophotonics and Molecular Imaging Research Center (BMIRC), National Yang-Ming University, Taipei, Taiwan

* These authors have contributed equally in this work

Correspondence to:

Jeng-Jong Hwang, email:

Keywords: adoptive T cell transfer, bioluminescent imaging, doxorubicin, NF-κB, paclitaxel, Immunology and Microbiology Section, Immune response, Immunity

Received: August 30, 2015 Accepted: November 25, 2015 Published: December 16, 2015

Abstract

Ex vivo expansion of CD8+ T-cells has been a hindrance for the success of adoptive T cell transfer in clinic. Currently, preconditioning with chemotherapy is used to modulate the patient immunity before ACT, however, the tumor microenvironment beneficial for transferring T cells may also be damaged. Here preconditioning with single low dose of doxorubicin or paclitaxel combined with fewer CD8+ T-cells was investigated to verify whether the same therapeutic efficacy of ACT could be achieved. An E.G7/OT1 animal model that involved adoptive transfer of OVA-specific CD8+ T-cells transduced with a granzyme B promoter-driven firefly luciferase and tomato fluorescent fusion reporter gene was used to evaluate this strategy. The result showed that CD8+ T-cells were activated and sustained longer in mice pretreated with one low-dose Dox or Tax. Enhanced therapeutic efficacy was found in Dox or Tax combined with 2x106 CD8+ T-cells and achieved the same level of tumor growth inhibition as that of 5x106 CD8+ T-cells group. Notably, reduced numbers of Tregs and myeloid derived suppressor cells were shown in combination groups. By contrast, the number of tumor-infiltrating cytotoxic T lymphocytes and IL-12 were increased. The NF-κB activity and immunosuppressive factors such as TGF-β, IDO, CCL2, VEGF, CCL22, COX-2 and IL-10 were suppressed. This study demonstrates that preconditioning with single low dose Dox or Tax and combined with two fifth of the original CD8+ T-cells could improve the tumor microenvironment via suppression of NF-κB and its related immunosuppressors, and activate more CD8+ T-cells which also stay longer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6628